The invention relates to an oncolytic virus Ad-TD-hIL12 for targeted treatment of human tumors and an application thereof. The virus is preserved in China Center for Type Culture Collection with a preservation number of CCTCC NO: V201031. The carrier of the virus is C-subtype 5-type adenovirus Ad5 with three genes (E1A-CR2, E1B19K and E3gp-19K) deleted and E3gp-19K promoter used to express p35 and p40 subunit gene sequences of human IL12. The virus can reproduce dissolved tumor cells in tumor cells by infecting the tumor cells and generate high-level hIL12 with multiple anti-tumor functions in tumor tissues. The hIL12 has the function of resisting tumor angiogenesis, can adjust immuno competence of a human body, enables an organism to generate anti-tumor specific immunity capacity, kills distant metastatic tumor cells and prevents tumor reoccurrence. As a result, the hIL 12 can serve as a targeted genetic engineering medicament for treating various solid tumors, can not only be applied to tumor intrathecal injection but also applied to enterocoelia and chest intrathecal injection without triggering obvious side-effects, thus achieving good curative effects and security.